BofA lowered the firm’s price target on Cencora (COR) to $360 from $380 and keeps a Neutral rating on the shares. Heading into 2026, the firm maintains its positive view on the drug distributor group and updates its price targets to reflect peer group multiple changes.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora price target lowered to $392 from $395 at Baird
- Cencora’s Strategic Acquisition: Hold Rating Amid Limited Near-Term Financial Upside
- Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
- Cencora backs FY26 adjusted EPS view $17.45-$17.75, consensus $17.67
- Cencora Announces Acquisition of OneOncology for $3.6 Billion